Top Page
Xbrane Biopharma AB
(Berlin:XBRANE)
Xbrane Biopharma AB (XBRANE) vs. iShares MSCI Sweden ETF (EWD)
Xbrane Biopharma AB Business Overview & Revenue Model
Xbrane Biopharma AB Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 198.70M | 238.73M | 57.62M | 11.53M | 6.82M |
| Gross Profit | 180.47M | 35.39M | 41.04M | -684.00K | 2.45M |
| EBITDA | -181.97M | -282.03M | -149.34M | -167.59M | -213.07M |
| Net Income | -266.22M | -388.17M | -172.23M | -191.01M | -226.79M |
Balance Sheet | |||||
| Total Assets | 842.43M | 653.51M | 690.51M | 688.43M | 463.76M |
| Cash, Cash Equivalents and Short-Term Investments | 124.33M | 65.40M | 193.99M | 295.18M | 243.14M |
| Total Debt | 191.72M | 231.48M | 38.22M | 44.38M | 6.26M |
| Total Liabilities | 633.89M | 482.17M | 265.63M | 256.69M | 206.06M |
| Stockholders Equity | 208.54M | 171.34M | 424.89M | 431.74M | 257.71M |
Cash Flow | |||||
| Free Cash Flow | -185.97M | -423.45M | -254.04M | -296.96M | -242.26M |
| Operating Cash Flow | -133.73M | -406.68M | -193.92M | -219.61M | -238.41M |
| Investing Cash Flow | -52.25M | -16.77M | -60.13M | -77.35M | -3.85M |
| Financing Cash Flow | 243.62M | 298.70M | 148.86M | 349.37M | 322.72M |
Xbrane Biopharma AB Technical Analysis
Xbrane Biopharma AB Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | kr1.21B | ― | ― | 1.72% | 32.54% | ||
58 Neutral | kr427.48M | ― | -47.73% | ― | 45.52% | 93.35% | |
58 Neutral | €490.12M | ― | -18.79% | ― | ― | 21.85% | |
52 Neutral | kr5.61B | 10.15 | -63.86% | 2.10% | 27.11% | 26.73% | |
51 Neutral | kr402.16M | ― | -24.61% | ― | 56.48% | 40.18% | |
36 Underperform | kr264.66M | ― | -54.29% | ― | -100.00% | -17.35% | |
32 Underperform | kr397.30M | ― | -205.65% | ― | ― | 24.25% |
Xbrane Biopharma AB Corporate Events
Xbrane Biopharma AB has published a disclosure document for the admission of newly issued shares to trading on Nasdaq Stockholm. This follows a directed share issue approved by the company’s board and an extraordinary general meeting, involving over a billion new shares. Certain investments in the directed issue may require review by the Swedish Inspectorate for Strategic Products, with trading expected in August 2025. Pareto Securities and Baker & McKenzie Advokatbyrå KB are advising on the process.
Xbrane Biopharma AB held an extra general meeting where it approved a directed issue of shares, deviating from shareholders’ preferential rights. This strategic move is intended to strengthen the company’s financial position, attract reputable long-term shareholders, and support its ongoing development and commercialization of biosimilars. The decision to opt for a directed issue over a rights issue is based on factors such as time efficiency, cost-effectiveness, and minimizing market risk exposure.
Xbrane Biopharma AB has announced a directed share issue, subject to approval by an Extraordinary General Meeting, to raise approximately SEK 240 million. This funding will support the company’s regulatory processes, production costs, and general corporate purposes, positioning Xbrane to capitalize on its biosimilar products, Ximluci® and Xdivane™, and potentially achieve cash-flow positivity. The recent transaction with Alvotech, involving the sale of a biosimilar candidate and organizational restructuring, is expected to significantly reduce Xbrane’s fixed costs and enhance its financial flexibility, enabling a stronger focus on its core biosimilar programs.
Xbrane Biopharma AB has announced an extra general meeting to discuss a proposed directed issue of shares, which involves issuing up to 1,043,478,260 new shares. This move is aimed at raising capital, with a total potential increase in share capital of SEK 233,933,281.222894. The subscription price is set at SEK 0.23 per share, determined through an accelerated bookbuilding procedure. This strategic decision is expected to strengthen the company’s financial position and support its market expansion efforts, potentially impacting stakeholders by enhancing the company’s capability to compete in the biosimilar market.
Xbrane Biopharma AB announced a directed issue of shares worth approximately SEK 200 million to institutional and qualified investors. This move is aimed at financing regulatory processes, paying suppliers, and supporting general corporate purposes. The company recently completed a transaction with Alvotech, selling its biosimilar candidate and parts of its organization, which is expected to reduce annual fixed costs significantly. The directed issue is seen as a strategic decision to strengthen the company’s financial position, diversify its shareholder base, and support the development and commercialization of its biosimilars.
Xbrane Biopharma has completed the sale of its biosimilar candidate XB003 and parts of its organization to Alvotech for approximately SEK 275 million. This transaction strengthens Xbrane’s financial position, allowing the company to focus on its remaining programs, particularly Ximluci and Xdivane, and continue its work in biosimilar development to create value for shareholders and patients.
Xbrane Biopharma AB has re-submitted its Biologics License Application to the US FDA for its biosimilar candidate to LUCENTIS® (ranibizumab), aimed at treating conditions such as age-related macular degeneration. The FDA has set a decision date for October 2025, contingent on successful re-inspections of manufacturing sites. This move underscores Xbrane’s commitment to providing cost-effective treatment alternatives and could enhance its position in the biosimilar market.
Xbrane Biopharma AB announced a strategic move to sell its biosimilar candidate XB003 and parts of its organization to Alvotech for approximately SEK 275 million. This transaction is expected to strengthen Xbrane’s financial position by reducing annual fixed costs by around SEK 120 million and allowing the company to focus on its core products, Ximluci® and Xdivane™, which are anticipated to generate significant revenue through royalties and profit sharing. The company also reported strong growth for Ximluci® in Europe and is progressing with regulatory processes in the US, while preparing for a clinical trial for Xdivane™.
Xbrane Biopharma AB’s annual general meeting resulted in several key resolutions, including the adoption of the income statement and balance sheet, the decision not to distribute dividends, and the re-election of board members and auditors. The meeting also established remuneration for directors and committee members and set guidelines for senior executive remuneration, while withdrawing a proposal for issuing shares due to insufficient support.